SLC22A5 and inflammatory bowel disease: At a false discovery rate (FDR) of 5%, we observed a significant enrichment of SLC22A4, SLC22A5, and P4HA2 genes for Crohn’s disease and inflammatory bowel disease (IBD) (S23A–S23C Figs).